Oncotarget

Research Papers:

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

Derrick S. Haslem _, Ingo Chakravarty, Gail Fulde, Heather Gilbert, Brian P. Tudor, Karen Lin, James M. Ford and Lincoln D. Nadauld

PDF  |  HTML  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2018; 9:12316-12322. https://doi.org/10.18632/oncotarget.24384

Metrics: PDF 959 views  |   HTML 2597 views  |   ?  


Abstract

Derrick S. Haslem1, Ingo Chakravarty2, Gail Fulde1, Heather Gilbert1, Brian P. Tudor1, Karen Lin1, James M. Ford3 and Lincoln D. Nadauld1,3

1Precision Genomics Program, Intermountain Healthcare, Saint George, UT, United States of America

2Navican Genomics, Intermountain Healthcare, San Diego, CA, United States of America

3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America

Correspondence to:

Lincoln D. Nadauld, email: lincoln.nadauld@imail.org

Keywords: precision medicine, oncology, outcomes, costs, overall survival

Received: May 17, 2017     Accepted: September 15, 2017     Published: February 02, 2018

ABSTRACT

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, we evaluated the overall survival and healthcare costs for each patient. We analyzed the outcomes of 22 patients who received genomic testing and targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015, and compared to 22 historically controlled patients (control) who received standard chemotherapy (N = 17) or best supportive care (N = 5). The median overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks for the control group (P = 0.008) when matching on age, gender, histological diagnosis and previous treatment lines. Average costs over the entire period were $2,720 per week for the targeted treatment group and $3,453 per week for the control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage cancer diagnoses found that those who received a targeted cancer treatment (N = 93) had 6.9% lower costs in the last 3 months of life compared with those who did not. These findings suggest that precision oncology may improve overall survival for refractory cancer patients while lowering average per-week healthcare costs, resource utilization and end-of-life costs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24384